Zevra Therapeutics (ZVRA) Stock Price, Quote, News & History | Benzinga

Zevra Therapeutics Inc (ZVRA) Stock Price, Quote, News & History

ZVRANASDAQ

Trade with Public

Trade with Public

$11.87

0.131.11%

Last update: Sep 1, 12:37 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$11.61

Close

-

Volume / Avg.

338.68K / 1.50M

Day Range

$11.56 - $12.03

52 Wk Range

7.16 - 15.04

Market Cap

$704.89M

P/E Ratio

12.62

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

11.02%

Days to Cover

5.76

Recent Zevra Therapeutics Inc News

Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.

Avi Kapoor

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C, prompting a re-examination request.

Vandana Singh

Zevra Shares Jump After Selling SDX Portfolio For $50M

Zevra Therapeutics Inc. shares are trading higher on Monday after it agreed to sell its SDX Portfolio to Commave for $50 million.

Dylan Berman

This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Avi Kapoor

This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings page for more info. Consider buying COHU stock.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

33.40M

Investing Cash Flow (TTM)

106.72M

Financing Cash Flow (TTM)

-42.14M

Free Cash Flow (TTM)

32.62M

Capital Expenditure (TTM)

-775.00K

Net Change in Cash (TTM)

97.98M

Analyst Trends and Forecast

1

Mar

1

May

7

Jun

3

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$477.09M

PE Ratio (TTM)

12.62

PE Ratio (FWD)

11.19

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.14

PB Ratio (TTM)

3.20

Earnings Yield % (TTM)

7.92%

Earnings Yield % (FWD)

8.94%

EV / EBITDA (TTM)

6.24

Price / EBITDA (TTM)

9.15

Price / Free Cash Flow (TTM)

21.46

Book Value / Share

$3.67

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$60.09M

Total Cash

$145.32M

Debt to Equity

0.01

Issuance of Debt (TTM)

-$60.09M

Repayment of Debt (TTM)

-$60.09M

Key Statistics

Open

$11.61

Close

-

Volume / Avg.

338.68K / 1.50M

Day Range

$11.56 - $12.03

52 Wk Range

7.16 - 15.04

Market Cap

$704.89M

P/E Ratio

12.62

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

11.02%

Days to Cover

5.76

About

Sector

Health Care

Industry

Pharmaceuticals

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Zevra Therapeutics (ZVRA) stock?

A

You can purchase shares of Zevra Therapeutics (NASDAQ:ZVRA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Zevra Therapeutics (ZVRA) competitors?

A

Other companies in Zevra Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Zevra Therapeutics (ZVRA) stock?

A

Zevra Therapeutics has a consensus price target of $23.50.

Q

What is the current price for Zevra Therapeutics (ZVRA)?

A

The stock price for Zevra Therapeutics (NASDAQ: ZVRA) is $11.87 last updated September 1, 2026 at 12:37 PM EDT.

Q

Does Zevra Therapeutics (ZVRA) pay a dividend?

A

There are no upcoming dividends for Zevra Therapeutics.

Q

When is Zevra Therapeutics (NASDAQ:ZVRA) reporting earnings?

A

Zevra Therapeutics does not have any upcoming earnings scheduled.

Q

Is Zevra Therapeutics (ZVRA) going to split?

A

There is no upcoming split for Zevra Therapeutics.

Q

What sector and industry does Zevra Therapeutics (ZVRA) operate in?

A

Zevra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.